Shots:

• The ongoing P-IIb POC- open-label study involves assessing Encaleret (starting dose: 30 mg) in 6 patients for the treatment of ADH1
• The results showed normalization of blood calcium and urine calcium- well-tolerated and consistent mineral responses with no serious AEs- and no AEs of moderate or severe intensity reported after 5 days- at doses up to 180 mg
• Encaleret could be the 1^st approved therapy option indicated specifically for the treatment of ADH1- if the development program is successful

 ­ Ref: PRNewswire | Image: PRNewswire